姜黄素逆转非小细胞肺癌分子靶向药物耐药的研究进展  

Research progress of reversion molecular targeted drug resistance in non-small cell lung cancer by curcumin

作　　者：于梦迪[1] 王明霞[1] 王海东 YU Meng di;WANG Ming xia;WANG Hai dong(Pharmaceutical Dept, Fourth Hospital of Hebei Medical University, Shijiazhuang050011,China)

机构地区：[1]河北医科大学第四医院药学部,河北石家庄050011

出　　处：《中国药理学通报》2017年第12期1633-1637,共5页Chinese Pharmacological Bulletin

基　　金：河北省人力资源和社会保障厅留学回国人员科技活动择优资助项目(No 20100313);河北省中医药管理局科研计划项目(No 2013161)

摘　　要：近年来,随着分子生物学的飞速发展,非小细胞肺癌(NSCLC)的分子靶向治疗成为研究的热点。靶向治疗相对于传统化疗具有很大优势,但是在进行靶向治疗过程中不可避免地遇到耐药问题。耐药问题成为了靶向药物对NSCLC患者治疗的重大障碍。姜黄素是姜黄植物根茎提取物的主要活性成分,具有广泛的抗肿瘤等药理活性,一些研究已证实姜黄素能对许多肿瘤的耐药具有逆转作用。然而,姜黄素对靶向药物耐药的逆转作用的报道并不多。该文总结了国内外相关文献,对靶向药物的主要耐药机制和姜黄素对其耐药的相关作用研究进展进行综述。In recent years,molecular biology has rapidly developed,and molecular targeted therapy of non small cell lung cancer has become a hot spot for the research.Although the targeted therapy has a big advantage compared with traditional chemotherapy,it is inevitable to encounter drug resistance in targeted therapy.Therefore,drug resistance has become the significant obstacle of targeted drugs for the treatment of non small cell lung cancer(NSCLC).Curcumin is the main extract of tumeric rhizome,which harbours a wide range of antitumor activities,and several studies have identified that curcumin exhibits reversion drug resistance against a variety of cancer cells.However,there are few studies on curcumin reversion molecular targeted drug resistance.This review summarizes the recent progress in resistance mechanism of targeted drug and the reversion resistance of curcumin.

关 键 词：分子靶向药物 药物耐药 非小细胞肺癌 姜黄素 耐药机制 逆转耐药 

分 类 号：R-05[医药卫生] R282.71